US Brand Name(s): Rozlytrek
Use of Entrectinib in Cancer Treatment
Entrectinib has an authorization to treat the following conditions:
- The presence of ROS in non-small cell lung cancer. Experts use it in people who have cancer that has progressed to other regions of their body (spread to other parts of the body).
- Solid tumors with an NTRK gene fusion do not have a drug-resistance mutation in one of the TRK proteins. Doctors prescribe it for adults and children aged 12 and up who have cancer which has spread or cannot have a surgical removal; which has become worse after other treatments, or which cannot cure with other therapies.
The FDA’s Accelerated Approval Program has authorized this usage. Confirmatory trials must prove that entrectinib has a clinical benefit in these individuals as a condition of approval.
Researchers are also researching Entrectinib for use in the treatment of various cancers.
Detailed scientific definition- Definition from the NCI Drug Dictionary
Entrectinib Information on MedlinePlus – A summary of key information regarding this medicine in layman’s terms, which may contain the following:
Cautions about this medicine; what are its uses and how to use it; what you should tell your doctor before taking it; things you should know about it before using it, other drugs that might interact with it; and possible negative effects.
Experts are frequently investigating drugs to see whether they can treat or prevent conditions other than those with authorization. This patient information leaflet only covers authorized uses of the medications. However, much of the material might also apply to authorized uses being investigated.
